A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)
Clinical trial NCT05876832 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT05876832
- Sponsor
- Shijiazhuang Yiling Pharmaceutical Co. Ltd
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-06-15
- Primary completion
- 2027-07-01
- Enrollment
- 312
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.